FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972504039> ?p ?o ?g. }

• W1972504039 endingPage "3056" @default.
• W1972504039 startingPage "3051" @default.
• W1972504039 abstract "Abstract Objective Anti–RNA polymerase I/III (anti–RNAP I/III) antibodies are clinically useful markers of scleroderma, and their presence is associated with diffuse skin disease and an increased risk of cardiac and kidney involvement. Although RNAP I antibodies localize to the nucleolus, nucleolar staining by many anti‐RNAP antibody–positive sera is not always observed. Nucleolar staining by anti‐RNAP antibody–positive sera was examined by double staining with antifibrillarin antibodies to evaluate whether nucleolar staining can be used as a screening test for anti–RNAP I/III antibodies. In addition, the relationships between nucleolar staining and levels of anti–RNAP III antibodies were examined by enzyme‐linked immunosorbent assay (ELISA) and immunoprecipitation (IP) assay. Methods Sera were tested using immunofluorescent antinuclear antibodies on HEp‐2 cell slides, by anti–RNAP III ELISA, and by IP assay using 35 S‐labeled K562 cell extract. Nucleolar staining by anti‐RNAP antibody IP‐positive sera was confirmed by double staining using antifibrillarin monoclonal antibodies. The levels of anti–RNAP III antibodies were quantitated by ELISA and by IP assay using a serially diluted reference serum as a standard, and their relationship was analyzed. Results All 18 anti–RNAP I/III antibody–positive sera showed nuclear speckled patterns, but nucleolar staining was readily noticeable in only 44% of the sera. A positive correlation was found between ELISA and IP units for anti–RNAP III antibodies. The levels of anti–RNAP III antibodies and anti–RNAP I antibodies correlated well, with the exception of a few sera. Levels of anti–RNAP III antibodies were low in sera with nucleolar staining, whereas several sera with high levels of anti–RNAP I antibodies clearly showed nucleolar staining. Conclusion Although some sera positive for anti–RNAP I/III antibodies clearly stain nucleoli, nucleolar staining is inconsistent and cannot be used to screen for anti–RNAP I/III antibodies." @default.
• W1972504039 created "2016-06-24" @default.
• W1972504039 creator A5007952554 @default.
• W1972504039 creator A5016651473 @default.
• W1972504039 creator A5022870216 @default.
• W1972504039 creator A5029479045 @default.
• W1972504039 creator A5034991389 @default.
• W1972504039 creator A5040084135 @default.
• W1972504039 creator A5046006313 @default.
• W1972504039 creator A5066760806 @default.
• W1972504039 creator A5068766449 @default.
• W1972504039 creator A5069421294 @default.
• W1972504039 creator A5085351598 @default.
• W1972504039 date "2006-08-31" @default.
• W1972504039 modified "2023-10-12" @default.
• W1972504039 title "Nucleolar staining cannot be used as a screening test for the scleroderma marker anti–RNA polymerase I/III antibodies" @default.
• W1972504039 cites W1579947132 @default.
• W1972504039 cites W1963640575 @default.
• W1972504039 cites W1967880575 @default.
• W1972504039 cites W1969670908 @default.
• W1972504039 cites W1973530039 @default.
• W1972504039 cites W1980442679 @default.
• W1972504039 cites W1995379503 @default.
• W1972504039 cites W2007995865 @default.
• W1972504039 cites W2035705144 @default.
• W1972504039 cites W2048675014 @default.
• W1972504039 cites W2056293311 @default.
• W1972504039 cites W2121599003 @default.
• W1972504039 cites W2129498411 @default.
• W1972504039 cites W2133518113 @default.
• W1972504039 doi "https://doi.org/10.1002/art.22043" @default.
• W1972504039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16948135" @default.
• W1972504039 hasPublicationYear "2006" @default.
• W1972504039 type Work @default.
• W1972504039 sameAs 1972504039 @default.
• W1972504039 citedByCount "34" @default.
• W1972504039 countsByYear W19725040392013 @default.
• W1972504039 countsByYear W19725040392015 @default.
• W1972504039 countsByYear W19725040392016 @default.
• W1972504039 countsByYear W19725040392017 @default.
• W1972504039 countsByYear W19725040392019 @default.
• W1972504039 countsByYear W19725040392020 @default.
• W1972504039 countsByYear W19725040392022 @default.
• W1972504039 countsByYear W19725040392023 @default.
• W1972504039 crossrefType "journal-article" @default.
• W1972504039 hasAuthorship W1972504039A5007952554 @default.
• W1972504039 hasAuthorship W1972504039A5016651473 @default.
• W1972504039 hasAuthorship W1972504039A5022870216 @default.
• W1972504039 hasAuthorship W1972504039A5029479045 @default.
• W1972504039 hasAuthorship W1972504039A5034991389 @default.
• W1972504039 hasAuthorship W1972504039A5040084135 @default.
• W1972504039 hasAuthorship W1972504039A5046006313 @default.
• W1972504039 hasAuthorship W1972504039A5066760806 @default.
• W1972504039 hasAuthorship W1972504039A5068766449 @default.
• W1972504039 hasAuthorship W1972504039A5069421294 @default.
• W1972504039 hasAuthorship W1972504039A5085351598 @default.
• W1972504039 hasBestOaLocation W19725040391 @default.
• W1972504039 hasConcept C149443304 @default.
• W1972504039 hasConcept C153911025 @default.
• W1972504039 hasConcept C159654299 @default.
• W1972504039 hasConcept C163764329 @default.
• W1972504039 hasConcept C183873130 @default.
• W1972504039 hasConcept C190062978 @default.
• W1972504039 hasConcept C203014093 @default.
• W1972504039 hasConcept C204232928 @default.
• W1972504039 hasConcept C21269302 @default.
• W1972504039 hasConcept C542903549 @default.
• W1972504039 hasConcept C54355233 @default.
• W1972504039 hasConcept C55493867 @default.
• W1972504039 hasConcept C74864618 @default.
• W1972504039 hasConcept C86803240 @default.
• W1972504039 hasConceptScore W1972504039C149443304 @default.
• W1972504039 hasConceptScore W1972504039C153911025 @default.
• W1972504039 hasConceptScore W1972504039C159654299 @default.
• W1972504039 hasConceptScore W1972504039C163764329 @default.
• W1972504039 hasConceptScore W1972504039C183873130 @default.
• W1972504039 hasConceptScore W1972504039C190062978 @default.
• W1972504039 hasConceptScore W1972504039C203014093 @default.
• W1972504039 hasConceptScore W1972504039C204232928 @default.
• W1972504039 hasConceptScore W1972504039C21269302 @default.
• W1972504039 hasConceptScore W1972504039C542903549 @default.
• W1972504039 hasConceptScore W1972504039C54355233 @default.
• W1972504039 hasConceptScore W1972504039C55493867 @default.
• W1972504039 hasConceptScore W1972504039C74864618 @default.
• W1972504039 hasConceptScore W1972504039C86803240 @default.
• W1972504039 hasIssue "9" @default.
• W1972504039 hasLocation W19725040391 @default.
• W1972504039 hasLocation W19725040392 @default.
• W1972504039 hasOpenAccess W1972504039 @default.
• W1972504039 hasPrimaryLocation W19725040391 @default.
• W1972504039 hasRelatedWork W1974126462 @default.
• W1972504039 hasRelatedWork W1995011209 @default.
• W1972504039 hasRelatedWork W2005041621 @default.
• W1972504039 hasRelatedWork W2008134180 @default.
• W1972504039 hasRelatedWork W2066528777 @default.
• W1972504039 hasRelatedWork W2086072971 @default.
• W1972504039 hasRelatedWork W2123042378 @default.
• W1972504039 hasRelatedWork W2154427904 @default.

• next